Olanzapine orally disintegrating tablet: a review of efficacy and compliance.
Medication nonadherence, especially in psychiatric disorders, has been associated with treatment failure and other negative outcomes. Orally disintegrating formulations have been developed as an alternative to improve medication adherence. This report reviews the properties, efficacy, and safety profile of olanzapine as an orally disintegrating tablet, and explores their association with medication compliance compared with standard oral formulation. Medical literature, published on orally disintegrating formulation of olanzapine identified using Pubmed and EMBASE, was used. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Studies evaluating the biostability, biodisposability, pharmacokinetics, efficacy, and safety of orally disintegrating olanzapine as treatment of patients with psychiatric disorders were reviewed. Measurement tools included the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), Simpson-Angus Scale (SAS), Abnormal Involuntary Movement Scale, and Nursing Assessment of Medication Acceptance (NAMA). Orally disintegrating olanzapine, an effective atypical antipsychotic with an acceptable safety profile, can facilitate the burden of treatment on patients and caregivers due to its ease of administration. This is especially important in diseases such as schizophrenia and bipolar disorder, which can be chronic and require long-term treatment.
San
Luis
L
Servicio de Psiquiatría, Hospital San Igualada, Barcelona, Spain.
Casillas
Marta
M
Ciudad
Antonio
A
Gilaberte
Inmaculada
I
D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D001714:Bipolar Disorder / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems; D006801:Humans; D000077152:Olanzapine; D017063:Outcome Assessment, Health Care; D010349:Patient Compliance; D012559:Schizophrenia / Q000188:drug therapy*; D012995:Solubility; D013607:Tablets
D014150:Antipsychotic Agents; D013607:Tablets; D001569:Benzodiazepines; D000077152:Olanzapine
Psychopharmacology (Berl). 2004 Sep;175(3):389-90
15322727
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):541-2
17029723
Pharmacoeconomics. 2000 Aug;18(2):106-24
11067646
J Am Pharm Assoc (Wash). 2000 Jul-Aug;40(4):475-85
10932456
J Child Adolesc Psychopharmacol. 2004 Winter;14(4):617-20
15662155
J Clin Psychiatry. 2005 Nov;66(11):1493-4; author reply 1494
16420093
Drugs. 2001;61(1):111-61
11217867
Drug Saf. 2006;29(6):550-2; author reply 552
16752937
J Clin Psychopharmacol. 2007 Aug;27(4):392-4
17632224
Schizophr Bull. 1997;23(4):637-51
9366000
Schizophr Bull. 1994;20(2):297-310
7916162
Am J Psychiatry. 2004 Apr;161(4):692-9
15056516
Int J Neuropsychopharmacol. 2003 Jun;6(2):97-102
12890301
Drugs. 2004;64(23):2709-26
15537371
Can J Psychiatry. 2004 May;49(5):297-302
15198465
Schizophr Bull. 1995;21(3):419-29
7481573
Hum Psychopharmacol. 2007 Jan;22(1):11-5
17191265
Psychiatr Serv. 1999 May;50(5):667-73
10332904
Acta Psychiatr Scand Suppl. 2000;(407):83-6
11261648
Arch Gen Psychiatry. 1974 Nov;31(5):603-8
4374155
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003729
15846678
Gen Hosp Psychiatry. 2008 Jul-Aug;30(4):367-71
18585542
J Psychosoc Nurs Ment Health Serv. 2004 May;42(5):44-8
15182049
World J Biol Psychiatry. 2010 Oct;11(7):894-903
20653494
J Clin Psychiatry. 2006;67 Suppl 5:19-23
16822093
Medicina (Kaunas). 2006;42(12):1006-12
17211109
JAMA. 1990 Nov 21;264(19):2511-8
2232018
Eur Psychiatry. 2001 Aug;16(5):293-8
11514132
Can J Psychiatry. 2002 Oct;47(8):771-4
12420656
J Clin Psychiatry. 2003;64 Suppl 16:10-3
14680413
J Nerv Ment Dis. 2004 Jun;192(6):421-7
15167405
J Clin Pharmacol. 2006 Feb;46(2):164-71
16432268
Schizophr Bull. 1987;13(2):261-76
3616518
J Clin Psychopharmacol. 1997 Dec;17(6):472-7
9408810
Biol Psychiatry. 2001 Mar 15;49(6):487-99
11257234
Eur J Cancer Care (Engl). 2007 May;16(3):289-90
17508951
J Clin Psychopharmacol. 2006 Jun;26(3):333-5
16702903
Pharmacogenet Genomics. 2005 Apr;15(4):195-200
15864111
J Clin Psychiatry. 2006 Jul;67(7):1114-23
16889456
J Clin Psychiatry. 2003 Feb;64(2):119-22
12633119
J Pharm Pharmacol. 1998 Apr;50(4):375-82
9625481
Pharmacoepidemiol Drug Saf. 2003 Jul-Aug;12(5):423-4
12899119
Hum Psychopharmacol. 2008 Apr;23(3):211-6
18219624
Actas Esp Psiquiatr. 2007 Jan-Feb;35(1):47-51
17323225
CNS Drugs. 2005;19(2):147-64
15697328
Patient Prefer Adherence. 2007 Dec 20;1:19-27
19956444
Encephale. 2002 May-Jun;28(3 Pt 1):266-72
12091789
Am J Physiol. 1994 Jan;266(1 Pt 2):R284-91
8304552
Am J Med. 1997 Feb 17;102(2A):43-9
9217586
Eur Psychiatry. 2007 Oct;22(7):453-4
17761403
N Engl J Med. 2005 Aug 4;353(5):487-97
16079372
Clin Ther. 2007 Feb;29(2):290-304
17472821
Schizophr Bull. 1996;22(1):69-82
8685665